Compare Stocks: BPMX, ZURA, IRD, and AVTE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$14.42 -2.1%	$20.17	$89.95 ▼ $99.05	$417.96M	0.95	53,591 shs	525,819 shs
BPMX Biopharmx		$0.00	$0.25 ▼ $6.30	$111.86M	N/A	2.15 million shs	336,508 shs
IRD Opus Genetics	$4.76	$4.19	$1.50 ▼ $7.07	$393.41M	0.58	5.21 million shs	1.24 million shs
ZURA Zura Bio	$4.04	$5.46	$2.07 ▼ $7.44	$387.15M	-0.02	1.55 million shs	1.51 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	0.00%	-14.88%	-32.27%	-34.45%	+70.05%
BPMX Biopharmx	0.00%	0.00%	0.00%	0.00%	0.00%
IRD Opus Genetics	0.00%	-8.11%	+29.00%	+17.24%	+161.54%
ZURA Zura Bio	0.00%	-9.42%	-29.37%	-28.24%	+67.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$14.42 -2.1%	$20.17	$89.95 ▼ $99.05	$417.96M	0.95	53,591 shs	525,819 shs
BPMX Biopharmx		$0.00	$0.25 ▼ $6.30	$111.86M	N/A	2.15 million shs	336,508 shs
IRD Opus Genetics	$4.76	$4.19	$1.50 ▼ $7.07	$393.41M	0.58	5.21 million shs	1.24 million shs
ZURA Zura Bio	$4.04	$5.46	$2.07 ▼ $7.44	$387.15M	-0.02	1.55 million shs	1.51 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	0.00%	-14.88%	-32.27%	-34.45%	+70.05%
BPMX Biopharmx	0.00%	0.00%	0.00%	0.00%	0.00%
IRD Opus Genetics	0.00%	-8.11%	+29.00%	+17.24%	+161.54%
ZURA Zura Bio	0.00%	-9.42%	-29.37%	-28.24%	+67.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
BPMX Biopharmx	0.00	N/A	N/A	N/A
IRD Opus Genetics	2.89	Moderate Buy	$11.92	150.48% Upside
ZURA Zura Bio	2.86	Moderate Buy	$17.00	320.79% Upside

Current Analyst Ratings Breakdown

Latest BPMX, ZURA, IRD, and AVTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	IRD Opus Genetics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$10.00 ➝ $13.00
9/9/2026	IRD Opus Genetics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$13.00 ➝ $16.00
9/9/2026	IRD Opus Genetics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$10.00 ➝ $20.00
9/9/2026	IRD Opus Genetics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
9/9/2026	IRD Opus Genetics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
9/9/2026	IRD Opus Genetics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
8/12/2026	ZURA Zura Bio	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$15.00 ➝ $22.00
8/12/2026	ZURA Zura Bio	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$15.00 ➝ $20.00
8/11/2026	IRD Opus Genetics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/7/2026	IRD Opus Genetics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$10.00 ➝ $9.00
7/29/2026	IRD Opus Genetics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
BPMX Biopharmx	N/A	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	$14.20M	27.71	N/A	N/A	$0.22 per share	21.64
ZURA Zura Bio	N/A	N/A	N/A	N/A	$1.38 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	N/A
BPMX Biopharmx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	-$49.59M	-$1.35	N/A	N/A	N/A	-1,091.82%	-338.88%	-150.13%	11/11/2026 (Estimated)
ZURA Zura Bio	-$99.35M	-$1.13	N/A	N/A	N/A	N/A	-56.13%	-50.15%	11/12/2026 (Estimated)

Latest BPMX, ZURA, IRD, and AVTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ZURA Zura Bio	-$0.1913	-$0.21	-$0.0187	-$0.21	N/A	N/A
8/6/2026	Q2 2026	IRD Opus Genetics	-$0.1567	-$0.14	+$0.0167	-$0.14	$2.63 million	$0.76 million
6/30/2026	Q2 2026	ZURA Zura Bio	N/A	-$0.21	N/A	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
BPMX Biopharmx	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	8.78	8.78
BPMX Biopharmx	N/A	N/A	N/A
IRD Opus Genetics	N/A	12.19	12.19
ZURA Zura Bio	N/A	12.90	12.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
BPMX Biopharmx	N/A
IRD Opus Genetics	14.97%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	24.90%
BPMX Biopharmx	N/A
IRD Opus Genetics	11.70%
ZURA Zura Bio	12.37%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
BPMX Biopharmx	17	18.28 million	N/A	Not Optionable
IRD Opus Genetics	28	82.65 million	72.98 million	N/A
ZURA Zura Bio	40	95.83 million	83.98 million	Optionable

BPMX, ZURA, IRD, and AVTE Headlines

Recent News About These Companies

Zura Bio stock extends multi-month rally on strong pipeline expectations

September 20, 2026 | ad-hoc-news.deA

Zura Bio Limited Class A Ordinary Shares

September 19, 2026 | livemint.com

Zura Bio Limited (ZURA) Latest Press Releases & Corporate News - Yahoo Finance

September 17, 2026 | finance.yahoo.com

Zura Bio (ZURA) Hits Enrollment Milestones As Losses Widen Sharply

September 11, 2026 | finance.yahoo.com

Zura Bio Limited (NASDAQ:ZURA) Receives Average Rating of "Moderate Buy" from Analysts

September 11, 2026 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Shares Down 7.2% - Time to Sell?

September 9, 2026 | marketbeat.com

Montanova Capital LLC Acquires 376,000 Shares of Zura Bio Limited $ZURA

September 1, 2026 | marketbeat.com

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 21, 2026 | businesswire.com

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

August 11, 2026 | businesswire.com

Zura Bio Stock (NASDAQ:ZURAW), Analyst Ratings, Price Targets, Predictions

July 27, 2026 | benzinga.com

William Blair Starts Zura Bio (ZURA) at Outperform

July 14, 2026 | uk.finance.yahoo.com

Licensing a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist

July 9, 2026 | businesswire.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Qiagen (QGEN) and Zura Bio (ZURA)

July 9, 2026 | theglobeandmail.com

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

June 29, 2026 | finance.yahoo.com

Zura Bio (ZURA) Gets a Buy from Oppenheimer

June 13, 2026 | theglobeandmail.com

Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation

June 3, 2026 | finance.yahoo.com

Zura Bio Announces Board Resignation, Governance Stability Affirmed

May 22, 2026 | tipranks.com

Analysts Are Bullish on These Healthcare Stocks: Silence Therapeutics (SLN), Zura Bio (ZURA)

May 11, 2026 | theglobeandmail.com

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

May 7, 2026 | businesswire.com

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 4, 2026 | businesswire.com

Zura Bio Limited Class A

April 24, 2026 | edition.cnn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BPMX, ZURA, IRD, and AVTE Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

$14.42 -0.31 (-2.10%)

As of 09/25/2026

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Biopharmx NYSEAMERICAN:BPMX

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.

Opus Genetics NASDAQ:IRD

$4.76 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$4.73 -0.03 (-0.63%)

As of 09/25/2026 07:30 PM Eastern

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

Zura Bio NASDAQ:ZURA

$4.04 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$4.11 +0.07 (+1.73%)

As of 09/25/2026 07:30 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BPMX, ZURA, IRD, and AVTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BPMX, ZURA, IRD, and AVTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BPMX, ZURA, IRD, and AVTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BPMX, ZURA, IRD, and AVTE Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

Biopharmx NYSEAMERICAN:BPMX

Opus Genetics NASDAQ:IRD

Zura Bio NASDAQ:ZURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BPMX, ZURA, IRD, and AVTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BPMX, ZURA, IRD, and AVTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BPMX, ZURA, IRD, and AVTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BPMX, ZURA, IRD, and AVTE Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

Biopharmx NYSEAMERICAN:BPMX

Opus Genetics NASDAQ:IRD

Zura Bio NASDAQ:ZURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools